Silexion Therapeutics Corp - 8-K Filing
Silexion Therapeutics reports positive preclinical findings for SIL204, demonstrating endogenous systemic uptake in KRAS-driven cancers. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits (d) Exhibits 99)
Tickers: $SLXN